Plasma Fractionation Market Overview
The Global Blood Plasma Fractionation Market 2023 Research Report is a professional and in-depth study of the current state of Blood Plasma Fractionation Market.
Cohn and colleagues invented plasma fractionation, the first large-scale protein purification method, nearly 60 years ago. Human serum albumin (HSA), immunoglobulin (IG), coagulation factor VIII, and protease inhibitors are currently therapeutically significant proteins. The global Plasma Fractionation market is expected to grow at a significant rate in the coming years.
The global plasma fractionation market is expected to be propelled by an increase in demand for plasma proteins, increased investment in innovation, and an increase in the occurrence of uncommon diseases around the world. The plasma fractionation industry has been investing in the research and development of new plasma protein therapies, which have resulted in innovative medicines for patients’ benefit. Furthermore, increased investment in research and development leads to technological advances in efficient and cost-effective processes for fractionating proteins from plasma, boosting the plasma fractionation market.
On the negative side, increasing market penetration by recombinant factors and strict regulations and reimbursement problems are key factors limiting the growth of the global plasma fractionation market.
GET A SAMPLE COPY OF THIS REPORT @ https://www.datalibraryresearch.com/sample-request/blood-plasma-fractionation-market-469
|Market size available for years||2023–2030|
|Base year considered||2023|
|Forecast unit||Value (USD Million)|
|Segments covered||Product Type, Applications, End use, and Region|
|Regions covered||North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)|
|Companies covered||CSL Limited, Shire plc, Sanquin, Biotest AG., GRIFOLS, Baxter International Inc., Kedrion, Octapharma and China Biologic Products Holdings, Inc.|
Covid-19 Impact on Plasma Fractionation Market
In addition, the current Plasma Fractionation Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Plasma Fractionation Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Plasma Fractionation Market Segment Overview
Based on Product Type, the Immunoglobulin segment dominates the global plasma fractionation market. This is due to the increased occurrence of autoimmune diseases such as primary humoral immunodeficiency (PIDD), multiple sclerosis, immune thrombocytopenia purpura (ITP), autoimmune hemolytic anemia, and Kawasaki syndrome. This aspect increases the rate of adoption of immunoglobulins, which in turn boosts the market. Moreover, according to application, neurology is another important segment in the global plasma fractionation market. An increase in the number of neurological disorders enhances the growth of the segment.
Plasma Fractionation Market, By Product Type
- Intravenous Immunoglobulin
- Subcutaneous Immunoglobulin
- Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Factor XIII
- Prothrombin Complex Concentrate
- Von Willebrand Factor
- Fibrinogen Concentrates
- Protease Inhibitors
Plasma Fractionation Market, By Application
· Critical Care
Plasma Fractionation Market, By End User
· Hospitals and Clinics
· Clinical Research Laboratories
· Academic Institutes
Plasma Fractionation Regional Overview
Region-Wise, North America, and Europe are two major regions for the global Plasma Fractionation market. The high occurrence of infectious diseases such as cholera, influenza, and syphilis in North America propelled the demand for the utilization of plasma fractionation. Likewise, Europe accounted for a prominent share of the market. This is because of the presence of a large old age population that is more prone to infections. Similarly, because of the large patient population, inadequate sanitization, and low awareness of plasma fractionation products among the people in the region, Asia Pacific is considered a developing market for plasma fractionation.
Plasma Fractionation Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Plasma Fractionation Market, Key Players
· CSL Limited
· Shire plc
· Biotest AG.
· Baxter International Inc.
· Octapharma and China Biologic Products Holdings, Inc.
TABLE OF CONTENT:
1 Report Overview
2 Global Growth Trends
3 Market Share by Key Players
4 Breakdown Data by Type and Application
5 United States
9 Southeast Asia
11 Central & South America
12 International Players Profiles
13 Market Forecast 2023-2030
14 Analyst’s Viewpoints/Conclusions
If you have any special requirements, please let us know and we will offer you the report as you want.
ENQUIRE TO GET COMPLETE REPORT WITH DISCOUNT-Blood Plasma Fractionation MARKET FORECAST TO 2030@ https://www.datalibraryresearch.com/reports/blood-plasma-fractionation-market-469